This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
A Randomized, Double-Blind, Placebo-Controlled Phase I Trial of Inhalation Treatment of Recombinant TFF2/IFN Protein: A Multifunctional Candidate for Treatment of COVID-19 (preprint)
ssrn; 2022.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.4201398
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS